Vulcan Two Group PLC
206.00
GBX
+1.00
(+0.49%)
ISIN
GB00BTQLZH16
Return %
Stock
S&P 500
1Y
-15.92
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Michael Benjamin Kraftman
- Sector
- Finance
- Industry
- Investment managers
- Address
- London United Kingdom
- Website
- vulcantwo.com
- Similar Companies
- Business
- Vulcan Two Group PLC, operating as Molecule Group plc, is a United Kingdom-based healthcare technology and regulated digital pharmacy company that provides electronic prescription fulfillment, online clinical consultations, and veterinary healthcare solutions across business-to-business (B2B) and direct-to-consumer (B2C) channels. The company delivers its offerings through an integrated ePharmacy platform comprising three principal operating divisions: B2B digital prescribing infrastructure via CloudRx, which offers application programming interface (API) integration for digital health systems, electronic prescription management, regulatory compliance verification, pharmacy dispensing, and direct-to-patient medication delivery for private medical practices, telehealth providers, and independent prescribers; direct-to-consumer digital healthcare and pharmacy services via Webmed Pharmacy, which provides online medical consultations, clinician reviews, electronic prescribing, and confidential fulfillment of treatments across key health areas such as weight management, men's health, women's health, dermatology, sexual health, and general wellness; and regulated veterinary pharmacy retail via Hyperdrug Pharmaceuticals, which supplies prescription veterinary medicines, over-the-counter animal pharmaceuticals, nutritional supplements, parasite control treatments, equine healthcare supplies, and specialty animal care products to pet owners, veterinary professionals, and agricultural clients. In March 2026, the company transformed its business model from an investment vehicle into an operating ePharmacy group through the acquisitions of CloudRx, Webmed, and Hyperdrug for an aggregate consideration of up to £41.7 million, supported by a £40 million equity placement on the London Stock Exchange AIM market. In October 2026, the company completed a corporate rebranding and reorganization, officially changing its corporate name from Vulcan Two Group PLC to Molecule Group plc and updating its London Stock Exchange ticker symbol to MOL to establish a unified identity across its digital healthcare portfolio. Incorporated in 2025, the company is headquartered in London, United Kingdom, and conducts its primary commercial operations across the United Kingdom.